|
| Press Releases |
|
 |
|
| Thursday, July 31, 2025 |
|
|
Revenue of LEQEMBI(R) (Preliminary Basis) |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the global revenue (pre-audit basis) of the anti-amyloid-beta protofibril antibody "LEQEMBI(R)" (generic name: lecanemab) was JPY 23.1 billion for the first quarter of fiscal year 2025 (April 1, 2025 - June 30, 2025). more info >> |
|
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
|
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the latest findings demonstrating the benefits of continuous treatment with lecanemab-irmb (U.S. brand name: LEQEMBI(R)), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada, and virtually more info >> |
|
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
|
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai")and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher,"Biogen") announced today that results on investigational maintenance therapy with subcutaneous autoinjector (SCAI) of lecanemab-irmb (U.S. brand name: LEQEMBI(R)), an anti-amyloid beta (AB) protofibril* antibody for the treatment of early Alzheimer's disease (AD), were presented at the Alzheimer's Association International Conference(AAIC) 2025, held in Toronto, and virtually. more info >> |
|
| Monday, July 20, 2020 |
|
|
エーザイ、人事異動（2020年7月20日付）を発表 |
| エーザイ株式会社は本日、人事異動（2020年7月20日付）を以下のとおり発表しました。 more info >> |
|
| Thursday, July 31, 2025 |
|
|
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the two-year real-world study in the U.S of lecanemab (generic name, product name: LEQEBMI(R)), an anti-AB protofibril* antibody, was presented at the Alzheimer's Association International Conference (AAIC) 2025, held in Toronto, Canada and virtually more info >> |
|
| Tuesday, July 29, 2025 |
|
|
LENVIMA(R) (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that its in-house discovered tyrosine kinase inhibitor, "LENVIMA(R)" (generic name: lenvatinib mesylate), in combination with the anti-PD-1 antibody, pembrolizumab, and transarterial chemoembolization (TACE) has been approved by the National Medical Products Administration (NMPA) of China for unresectable, non-metastatic hepatocellular carcinoma. more info >> |
|
| Friday, July 25, 2025 |
|
|
Eisai Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has been included in the FTSE4Good Index Series for the 24th consecutive year since its initial inclusion in 2002. more info >> |
|
| Wednesday, July 23, 2025 |
|
|
Launch of Beova(R) Tablets in Thailand for Overactive Bladder |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and KYORIN Pharmaceutical Co., Ltd. (Headquarters: Chiyoda-ku, Tokyo, President and CEO: Yutaka Ogihara, "KYORIN") announced today that Eisai (Thailand) Marketing Co., Ltd. ("Eisai Thailand"), a subsidiary of Eisai, has launched overactive bladder treatment Beova(R) Tablets (generic name vibegron) in Thailand more info >> |
|
| Tuesday, July 22, 2025 |
|
|
Eisai To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer's Association International Conference 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings from its robust Alzheimer's disease (AD) pipeline and research, including our dual-acting, anti-amyloid beta (AB;) protofibril antibody for the treatment of AD, lecanemab (generic name, U.S. brand name: LEQEMBI(R)), and anti-MTBR (microtubule binding region) tau antibody, etalanetug (E2814), at the Alzheimer's Association International Conference (AAIC), being held in Toronto and virtually from July 27-31. more info >> |
|
| Wednesday, July 16, 2025 |
|
|
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the drug discovery research for Lecanemab (product name: "LEQEMBI"), a humanized anti-human soluble amyloid B (AB) protofibril monoclonal antibody indicated for early Alzheimer's disease (early AD*), which was co-developed by Eisai and BioArctic AB (Headquarters: Sweden; herein after, BioArctic), has received "The 9th Bioindustry Award" from the Japan Bioindustry Association (JBA). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
プロミセル社、JPモルガン2026年ヘルスケアカンファレンスで発表
Jan 10, 2026 20:00: JST
|
|
|
普瑞美細胞公司於摩根大通2026年醫療保健會議發表
Jan 10, 2026 19:00 HKT/SGT
|
|
|
普瑞美赛尔公司亮相摩根大通2026年医疗健康大会
Jan 10, 2026 19:00 HKT/SGT
|
|
|
PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference
Jan 10, 2026 07:00 HKT/SGT
|
|
|
賽力斯：以品牌和科技為基 開啟智慧豪華出行新紀元
Jan 9, 2026 16:07 HKT/SGT
|
|
|
赛力斯：以品牌和科技为基 开启智慧豪华出行新纪元
Jan 9, 2026 15:58 HKT/SGT
|
|
|
TOYOTA GAZOO Racing Announces GR Yaris MORIZO RR
Jan 9, 2026 16:03 JST
|
|
|
アルゼンチンサッカー協会、Verofaxと提携しファン向けAI体験を提供
Jan 9, 2026 15:00: JST
|
|
|
市值超800億 成功上市的MiniMax以「極致效率」重塑全球AGI新格局
Jan 9, 2026 14:34 HKT/SGT
|
|
|
市值超800亿 成功上市的MiniMax以「极致效率」重塑全球AGI新格局
Jan 9, 2026 14:26 HKT/SGT
|
|
|
Argentine Football Association (AFA) collabora con Verofax per offrire esperienze di IA ai tifosi
Jan 9, 2026 14:00 HKT/SGT
|
|
|
Argentine Football Association (AFA) se asocia con Verofax para ofrecer experiencias de IA a los aficionados
Jan 9, 2026 14:00 HKT/SGT
|
|
|
Argentine Football Association (AFA) s’associe à Verofax pour offrir des expériences d’IA aux fans
Jan 9, 2026 14:00 HKT/SGT
|
|
|
Argentine Football Association (AFA), Verofax와 협력 팬을 위한 AI 경험 제공
Jan 9, 2026 14:00 HKT/SGT
|
|
|
Argentine Football Association（AFA）攜手 Verofax 為球迷提供 AI 互動體驗
Jan 9, 2026 14:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
